alexa Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Genetics & Molecular Biology

Genetics & Molecular Biology

Journal of Molecular Imaging & Dynamics

Author(s): SchwarzDose J, Untch M, Tiling R, Sassen S, Mahner S,

Abstract Share this page

Abstract PURPOSE: To evaluate positron emission tomography (PET) using [(18)F]fluorodeoxyglucose (FDG) for prediction of histopathologic response early during primary systemic therapy of large or locally advanced breast cancer. PATIENTS AND METHODS: In a prospective multicenter trial, 272 FDG-PET scans were performed in 104 patients at baseline (n = 104) and after the first (n = 87) and second cycle (n = 81) of chemotherapy. The level and relative changes in standardized uptake value (SUV) of FDG uptake were assessed regarding their ability to predict histopathologic response. All patients underwent surgery after chemotherapy, and histopathologic response defined as minimal residual disease or gross residual disease served as the reference standard. RESULTS: Seventeen (16\%) of 104 patients were histopathologic responders and 87 were (84\%) nonresponders. All patients for whom baseline SUV was less than 3.0 (n = 24) did not achieve a histopathologic response. SUV decreased by 51\% +/- 18\% after the first cycle of chemotherapy in histopathologic responders (n = 15), compared with 37\% +/- 21\% in nonresponders (n = 54; P = .01). A threshold of 45\% decrease in SUV correctly identified 11 of 15 responders, and histopathologic nonresponders were identified with a negative predictive value of 90\%. Similar results were found after the second cycle when using a threshold of 55\% relative decrease in SUV. CONCLUSION: FDG-PET allows for prediction of treatment response by the level of FDG uptake in terms of SUV at baseline and after each cycle of chemotherapy. Moreover, relative changes in SUV after the first and second cycle are a strong predictor of response. Thus, FDG-PET may be helpful for individual treatment stratification in breast cancer patients. This article was published in J Clin Oncol and referenced in Journal of Molecular Imaging & Dynamics

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 2nd International Conference on Nuclear Medicine & Radiation Therapy
    July 27-28, 2017 Rome, Italy
  • 5th International Conference on Current Trends in Mass Spectrometry
    September 25-27, 2017 Atlanta, USA
  • 8th Global Mass Spectrometry Congress
    Dec 14-16, 2017 Dubai, UAE
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version